MCID: CLR109
MIFTS: 49

Colorectal Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Colorectal Adenocarcinoma

MalaCards integrated aliases for Colorectal Adenocarcinoma:

Name: Colorectal Adenocarcinoma 12 14
Adenocarcinoma of Large Intestine 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050861

Summaries for Colorectal Adenocarcinoma

Disease Ontology : 12 A colorectal cancer that derives from epithelial cells of glandular origin.

MalaCards based summary : Colorectal Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to sebaceous adenocarcinoma and villous adenoma. An important gene associated with Colorectal Adenocarcinoma is FABP6 (Fatty Acid Binding Protein 6), and among its related pathways/superpathways are Developmental Biology and fMLP Pathway. The drugs Bevacizumab and Iron have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and lung, and related phenotypes are Decreased viability and cellular

Related Diseases for Colorectal Adenocarcinoma

Diseases related to Colorectal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 264)
id Related Disease Score Top Affiliating Genes
1 sebaceous adenocarcinoma 30.3 EGFR KRAS TP53
2 villous adenoma 29.0 CDH1 CTNNB1 EGFR HRAS TP53
3 colorectal cancer 24.8 AURKA BRAF CDH1 CDX2 CEACAM5 CTNNB1
4 adenocarcinoma 11.0
5 colorectal adenoma 10.9
6 mirror polydactyly-vertebral segmentation-limbs defects syndrome 10.9 BRAF TP53
7 bone giant cell tumor 10.9 KRT20 KRT7
8 rectum adenoma 10.8 KRT20 KRT7
9 coloboma of inferior eyelid 10.8 BRAF KRAS TP53
10 pediatric infratentorial ependymoma 10.8 EGFR TP53
11 malignant syringoma 10.8 BRAF KRAS TP53
12 deep angioma 10.8 CEACAM5 TP53
13 pilocytic astrocytoma of cerebellum 10.8 BRAF TP53
14 mucoepidermoid thyroid carcinoma 10.8 CEACAM5 KRT7
15 breast cystic hypersecretory carcinoma 10.8 CEACAM5 KRT7
16 retinal detachment 10.8 KRT20 KRT7 TP53
17 steroid-induced glaucoma - borderline 10.7 KRT20 KRT7
18 bile duct mucinous adenocarcinoma 10.7 CDX2 KRAS KRT7
19 ludwig's angina 10.7 KRT20 KRT7
20 sensory system cancer 10.7 CDX2 KRT20 KRT7
21 lung occult small cell carcinoma 10.7 CDX2 KRT20 KRT7
22 fibroepithelial polyp of urethra 10.7 CDX2 KRT20 KRT7
23 chronic neutrophilic leukemia 10.7 CDX2 KRT20 KRT7
24 cervix erosion 10.7 CEACAM5 KRT7
25 ovarian melanoma 10.7 CDX2 KRT20 KRT7
26 retinal disease 10.7 KRT20 KRT7 TP53
27 spastic ataxia 3 10.7 CDX2 KRT20 TP53
28 human t-cell leukemia virus type 1 10.7 CDX2 KRT20 KRT7
29 lipid-cell variant infiltrating bladder urothelial carcinoma 10.7 CEACAM5 KRT7 TP53
30 congenital mesoblastic nephroma 10.7 EGFR KRAS TP53
31 postpoliomyelitis syndrome 10.7 CDX2 KRAS KRT20
32 secondary hyperparathyroidism of renal origin 10.7 EGFR KRT7 TP53
33 juvenile astrocytoma 10.7 BRAF EGFR TP53
34 glycogen storage disease due to lactate dehydrogenase deficiency 10.7 CTNNB1 TP53
35 vulva squamous cell carcinoma 10.6 CEACAM5 KRT20 KRT7
36 mixed oligodendroglioma-astrocytoma 10.6 CEACAM5 TP53
37 synovitis 10.6 CDX2 CEACAM5 KRT7
38 renal pelvis urothelial papilloma 10.6 CDH1 TP53
39 hordeolum 10.6 CEACAM5 KRT20 KRT7
40 paralytic ileus 10.6 CDX2 KRT20 KRT7
41 childhood teratoma of the ovary 10.6 CDH1 CDX2 KRT20
42 proliferative type fibrocystic change of breast 10.6 CDX2 CEACAM5 KRT7
43 atrophic gastritis 10.6 BRAF MLH1 TP53
44 giant cell tumor 10.6 CDX2 CEACAM5 KRT20
45 breast myoepithelial neoplasm 10.6 CTNNB1 KRAS TP53
46 gastrointestinal system cancer 10.6 BRAF KRT20 KRT7
47 split hand split foot nystagmus 10.6 BRAF HRAS TP53
48 mixed type thymoma 10.6 EGFR KRT7 TP53
49 brachyolmia 10.6 EGFR KRT20 TP53
50 periosteal osteogenic sarcoma 10.6 CTNNB1 KRT20 KRT7

Graphical network of the top 20 diseases related to Colorectal Adenocarcinoma:



Diseases related to Colorectal Adenocarcinoma

Symptoms & Phenotypes for Colorectal Adenocarcinoma

GenomeRNAi Phenotypes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.82 HRAS KRAS PIM2 AURKA EGFR BRAF
2 Decreased viability GR00106-A-0 10.82 KRAS
3 Decreased viability GR00173-A 10.82 CDK8
4 Decreased viability GR00221-A-1 10.82 KRAS PIM2 AURKA CDH1 CDK8 EGFR
5 Decreased viability GR00221-A-2 10.82 HRAS KRAS AURKA CDK8
6 Decreased viability GR00221-A-3 10.82 HRAS
7 Decreased viability GR00221-A-4 10.82 AURKA CDK8 EGFR BRAF
8 Decreased viability GR00231-A 10.82 AURKA
9 Decreased viability GR00301-A 10.82 KRAS PIM2 CDH1 CDK8 MSH2 BRAF
10 Decreased viability GR00381-A-1 10.82 KRAS BRAF
11 Decreased cell migration GR00055-A-1 9.97 AURKA BRAF CDK8 CTNNB1 EGFR HRAS
12 Decreased viability in esophageal squamous lineage GR00235-A 9.9 AURKA BRAF CDH1 CDK8 CTNNB1 FABP6
13 Decreased cella89culturea89derived Hepatitis C virus (HCVcc GR00234-A-2 9.5 BRAF CDK8 EGFR
14 Increased cell migration GR00055-A-3 9.43 CTNNB1 EGFR HRAS KRAS AURKA BRAF
15 Increased cell viability after pRB stimulation GR00230-A-1 8.92 PIM2 AURKA CDK8 EGFR

MGI Mouse Phenotypes related to Colorectal Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.23 TP53 CDX2 CTNNB1 EGFR KRAS KRT7
2 digestive/alimentary MP:0005381 10.13 MSH2 MUC2 TP53 BRAF CDH1 CDX2
3 homeostasis/metabolism MP:0005376 10.13 CDH1 CDX2 CTNNB1 EGFR FABP6 HRAS
4 endocrine/exocrine gland MP:0005379 10.07 BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
5 embryo MP:0005380 10.06 AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
6 mortality/aging MP:0010768 9.97 AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
7 integument MP:0010771 9.91 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
8 neoplasm MP:0002006 9.73 AURKA BRAF CDH1 CDX2 CTNNB1 EGFR
9 pigmentation MP:0001186 9.02 BRAF CTNNB1 EGFR KRAS TP53

Drugs & Therapeutics for Colorectal Adenocarcinoma

Drugs for Colorectal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 252)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
2
Iron Approved Phase 4,Phase 3 7439-89-6 23925
3
Zinc Approved Phase 4 7440-66-6 32051 23994
4
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
5 tannic acid Approved, Nutraceutical Phase 4
6 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
7 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Ferric Compounds Phase 4
9 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
10 Hepcidins Phase 4
11 Hypoglycemic Agents Phase 4,Phase 2,Phase 1
12 insulin Phase 4
13 Insulin, Globin Zinc Phase 4
14 Iron Supplement Nutraceutical Phase 4
15
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
16
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
17
Celecoxib Approved, Investigational Phase 3,Phase 2,Phase 1 169590-42-5 2662
18
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
19
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
20
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
21
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
22
Raltitrexed Approved, Investigational Phase 3,Phase 2 112887-68-0 104758
23
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
24
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
25
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
26
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
27
Tegafur Approved Phase 3,Phase 2 17902-23-7 5386
28
Floxuridine Approved Phase 3,Phase 2 50-91-9 5790
29
Glycerol Approved, Investigational Phase 3 56-81-5 753
30
Tinzaparin Approved Phase 3 9005-49-6, 9041-08-1 25244225
31
Dalteparin Approved Phase 3 9005-49-6
32
Nicotine Approved Phase 3 54-11-5 942 89594
33
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
34
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
36
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
37
Eniluracil Investigational Phase 3 59989-18-3
38
Vatalanib Investigational Phase 3 212141-54-3 151194
39
Doxil Approved June 1999 Phase 3,Phase 2 31703
40 calcium heparin Phase 3
41 Analgesics Phase 3,Phase 2,Phase 1
42 Alkylating Agents Phase 3,Phase 2,Phase 1
43 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
44 Adjuvants, Immunologic Phase 3,Phase 1,Phase 2
45 Micronutrients Phase 3,Phase 2,Phase 1,Early Phase 1
46 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
47 Semaxinib Phase 3,Phase 1,Phase 2
48 Mitomycins Phase 3,Phase 2,Phase 1
49 Cyclooxygenase 2 Inhibitors Phase 3,Phase 2
50 Cyclooxygenase Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 385)

id Name Status NCT ID Phase Drugs
1 A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma Completed NCT00097578 Phase 4
2 Intravenous Iron: Measuring Response in Anemic Surgical Patients Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
3 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
4 Endoscopic Detection of Dysplasia in Crohn 's Disease Patient Completed NCT01180452 Phase 4
5 Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial Not yet recruiting NCT02746432 Phase 4 Hyper insulinemic euglycemic clamp
6 J-Pouch Coloanal Anastomosis Compared With Side-to-End Coloanal Anastomosis After Radiation Therapy and Surgery to Remove the Rectum in Treating Patients With Rectal Adenocarcinoma Unknown status NCT00070005 Phase 3
7 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
8 Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00182715 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
9 Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Unknown status NCT00091312 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
10 Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer Unknown status NCT00005979 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
11 Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer Unknown status NCT00227747 Phase 3 capecitabine;oxaliplatin
12 Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00008281 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
13 Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer Unknown status NCT00003260 Phase 3 FOLFIRI regimen;FOLFOX regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
14 Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00006468 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
15 Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00021281 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium;semaxanib
16 Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Unknown status NCT00274872 Phase 2, Phase 3 fluorouracil;leucovorin calcium;oxaliplatin
17 Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil Unknown status NCT00389870 Phase 3 cyclosporine;irinotecan hydrochloride
18 Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00070213 Phase 3 FOLFOX regimen;capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
19 Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer Unknown status NCT00002893 Phase 3 fluorouracil;leucovorin calcium;raltitrexed
20 Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer Unknown status NCT00482222 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
21 Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases Completed NCT00265356 Phase 3
22 A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer Completed NCT00623805 Phase 3 Bevacizumab;Capecitabine;Oxaliplatin
23 Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00003594 Phase 3 irinotecan;fluorouracil;leucovorin calcium;oxaliplatin
24 Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon Completed NCT00085163 Phase 3 celecoxib;fluorouracil;leucovorin calcium
25 Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver Completed NCT00023868 Phase 3 FOLFIRI regimen;cisplatin;doxorubicin hydrochloride;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C
26 Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer Completed NCT00056446 Phase 3 Vatalanib
27 Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. Completed NCT00056459 Phase 3 Vatalanib
28 Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery Completed NCT00427310 Phase 3 fluorouracil;sodium heparin
29 A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum Completed NCT00145769 Phase 3 Short Course Adjuvent Chemotherapy;Long Course Adjuvant Chemotherapy;Concurrent Chemotherapy
30 Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer Completed NCT00064181 Phase 3 FOLFIRI regimen;capecitabine;celecoxib;fluorouracil;irinotecan hydrochloride;leucovorin calcium
31 Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer Completed NCT00003873 Phase 3 fluorouracil;eniluracil
32 Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery Completed NCT00392899 Phase 3 UFT adjuvant chemotherapy
33 Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer Completed NCT00026273 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
34 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
35 Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated Completed NCT00025337 Phase 3 oxaliplatin;leucovorin calcium;fluorouracil
36 Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery Completed NCT00660894 Phase 3 folinate calcium;tegafur-uracil;tegafur-gimeracil-oteracil potassium
37 Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery Completed NCT00265811 Phase 3 Folfox + Cetuximab;Folfox
38 Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM) Completed NCT00265824 Phase 3 bevacizumab;bevacizumab, erlotinib
39 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
40 Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases Completed NCT00268398 Phase 3 oxaliplatin, folinic acid, fluorouracil;oxaliplatin, irinotecan, folinic acid, fluorouracil
41 Combination Chemotherapy in Treating Patients With Resected Colon Cancer Completed NCT00378716 Phase 3 5-fluorouracil;leucovorin calcium;tegafur;uracil
42 Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer Completed NCT00062426 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
43 Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Completed NCT00303771 Phase 3 fluorouracil;irinotecan hydrochloride;leucovorin calcium
44 Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer Completed NCT00427713 Phase 3 capecitabine;oxaliplatin
45 Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer Completed NCT00008060 Phase 3 FOLFIRI regimen;FOLFOX regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
46 Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer Completed NCT00004885 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
47 Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer Completed NCT00003287 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
48 Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer Completed NCT00766155 Phase 3 capecitabine;oxaliplatin
49 Radiation Therapy With or Without Chemotherapy Before Surgery in Treating Patients With Stage II or Stage III Rectal Cancer Completed NCT00296608 Phase 3 fluorouracil;leucovorin calcium
50 SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed Completed NCT00002551 Phase 3 fluorouracil;leucovorin calcium;levamisole hydrochloride

Search NIH Clinical Center for Colorectal Adenocarcinoma

Genetic Tests for Colorectal Adenocarcinoma

Anatomical Context for Colorectal Adenocarcinoma

MalaCards organs/tissues related to Colorectal Adenocarcinoma:

39
Colon, Liver, Lung, Prostate, Testes, Lymph Node, Endothelial

Publications for Colorectal Adenocarcinoma

Articles related to Colorectal Adenocarcinoma:

(show top 50) (show all 577)
id Title Authors Year
1
Expression of pattern recognition receptor genes and mortality in patients with colorectal adenocarcinoma. ( 28533893 )
2017
2
Aldolase B Overexpression is Associated with Poor Prognosis and Promotes Tumor Progression by Epithelial-Mesenchymal Transition in Colorectal Adenocarcinoma. ( 28558381 )
2017
3
6-shogaol induces autophagic cell death then triggered apoptosis in colorectal adenocarcinoma HT-29 cells. ( 28641163 )
2017
4
Implications of inflammation and remodeling of the enteric glial cells in colorectal adenocarcinoma. ( 28730232 )
2017
5
Late recurrence of colorectal adenocarcinoma as a renal tumour by direct spread via the ureter. ( 28588649 )
2017
6
Salvia fruticosa Modulates mRNA Expressions and Activity Levels of Xenobiotic Metabolizing CYP1A2, CYP2E1, NQO1, GPx, and GST Enzymes in Human Colorectal Adenocarcinoma HT-29 Cells. ( 28718679 )
2017
7
Racial Disparities in Clinical Presentation and Survival Times Among Young-Onset Colorectal Adenocarcinoma. ( 28631085 )
2017
8
Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/I^-catenin signaling pathway in human colorectal adenocarcinoma. ( 28259923 )
2017
9
Clinicopathologic significance of TRAP1 expression in colorectal cancer: a large scale study of human colorectal adenocarcinoma tissues. ( 28088229 )
2017
10
Effects of proton beam irradiation on mitochondrial biogenesis in a human colorectal adenocarcinoma cell line. ( 28713989 )
2017
11
Does tumor size have its prognostic role in colorectal cancer? Re-evaluating its value in colorectal adenocarcinoma with different macroscopic growth pattern. ( 28760707 )
2017
12
Knockdown of PARP6 or survivin promotes cell apoptosis and inhibits cell invasion of colorectal adenocarcinoma cells. ( 28260087 )
2017
13
Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma. ( 28187432 )
2017
14
Expression of epithelial-mesenchymal transition and cancer stem cell markers in colorectal adenocarcinoma: Clinicopathological significance. ( 28677737 )
2017
15
Clinical and Histopathologic Features of Colorectal Adenocarcinoma in Crohn's Disease. ( 28654553 )
2017
16
Migration of mitochondrial DNA in the nuclear genome of colorectal adenocarcinoma. ( 28356157 )
2017
17
Eradication of HT-29 colorectal adenocarcinoma cells by controlled photorelease of CO from a CO-releasing polymer (photoCORP-1) triggered by visible light through an optical fiber-based device. ( 28866022 )
2017
18
miRNA biogenesis-associated RNase III nucleases Drosha and Dicer are upregulated in colorectal adenocarcinoma. ( 28943952 )
2017
19
Intermittent low dose irradiation enhances the effectiveness of radio- and chemo-therapy for human colorectal adenocarcinoma cell line HT-29. ( 28560404 )
2017
20
B2 adrenergic receptors and morphological changes of the enteric nervous system in colorectal adenocarcinoma. ( 28275305 )
2017
21
Gastrointestinal stromal tumor with synchronous colorectal adenocarcinoma. ( 28655207 )
2017
22
Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro. ( 28819759 )
2017
23
Human epidermal growth factor (Her-2) in gastric and colorectal adenocarcinoma. ( 28770892 )
2017
24
Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing. ( 27863258 )
2017
25
Hierarchical cluster analysis and chemical characterisation of Myrtus communis L. essential oil from Yemen region and its antimicrobial, antioxidant and anti-colorectal adenocarcinoma properties. ( 28068844 )
2017
26
Aurora Kinase A Is a Prognostic Marker in Colorectal Adenocarcinoma. ( 28013532 )
2017
27
FGFR2 Amplification in Colorectal Adenocarcinoma. ( 28835367 )
2017
28
miR-34a overexpression predicts poor prognostic outcome in colorectal adenocarcinoma, independently of clinicopathological factors with established prognostic value. ( 28624481 )
2017
29
Comparison of gene expression profiles of gingival carcinoma Ca9-22 cells and colorectal adenocarcinoma HT-29 cells to identify potentially important mediators of SLPI-induced cell migration. ( 28637988 )
2017
30
Common housekeeping proteins are upregulated in colorectal adenocarcinoma and hepatocellular carcinoma, making the total protein a better "housekeeper". ( 27556505 )
2016
31
Muir-Torre Syndrome Presenting as Sebaceous Adenocarcinoma and Invasive MSH6-Positive Colorectal Adenocarcinoma. ( 26933426 )
2016
32
Potent anti-angiogenic and cytotoxic effect of conferone on human colorectal adenocarcinoma HT-29 cells. ( 27002410 )
2016
33
Expression analysis and clinical significance of eIF4E, VEGF-C, E-cadherin and MMP-2 in colorectal adenocarcinoma. ( 27907907 )
2016
34
Cholest-4-en-3-one attenuates TGF-I^ responsiveness by inducing TGF-I^ receptors degradation in Mv1Lu cells and colorectal adenocarcinoma cells. ( 27401208 )
2016
35
Frequency of Her2/neu expression in colorectal adenocarcinoma: a study from developing South Asian Country. ( 27821098 )
2016
36
Toxicity and early outcomes of regorafenib in multiply pre-treated metastatic colorectal adenocarcinoma-experience from a tertiary cancer centre in India. ( 27004221 )
2016
37
High frequency of KRAS mutation in early onset colorectal adenocarcinoma: implications for pathogenesis. ( 27346571 )
2016
38
Anti-proliferative Effect of Engineered Neural Stem Cells Expressing Cytosine Deaminase and Interferon-I^ Against Lymph Node-derived Metastatic Colorectal Adenocarcinoma in Cellular and Xenograft Mouse Models. ( 27188205 )
2016
39
Loss of Hes1 expression is associated with poor prognosis in colorectal adenocarcinoma. ( 27476040 )
2016
40
Long-term use of lithium and risk of colorectal adenocarcinoma: a nationwide case-control study. ( 26867160 )
2016
41
Expressions of Inhibitors of DNA Binding-1 and Matrix Metalloproteinase-9 in Colorectal Adenocarcinoma Tissues and Their Correlations with Microvessel Density. ( 28065236 )
2016
42
A case of cutaneous metastasis of the scalp from colorectal adenocarcinoma. ( 27773160 )
2016
43
Computer Aided Diagnosis for Confocal Laser Endomicroscopy in Advanced Colorectal Adenocarcinoma. ( 27144985 )
2016
44
Transcriptional Regulation of Human Cytosolic Sulfotransferase 1C3 by Peroxisome Proliferator-Activated Receptor I^ in LS180 Human Colorectal Adenocarcinoma Cells. ( 27565680 )
2016
45
Clinicopathologic and Molecular Features of Colorectal Adenocarcinoma with Signet-Ring Cell Component. ( 27300552 )
2016
46
Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma. ( 27939727 )
2016
47
Clinicopathologic Significance of Extranodal Tumor Extension in Colorectal Adenocarcinoma with Regional Lymph Node Metastasis. ( 27195006 )
2016
48
Prognostic significance of the frequency of primary cilia in cells of small bowel and colorectal adenocarcinoma. ( 27837628 )
2016
49
A model of the spatial tumour heterogeneity in colorectal adenocarcinoma tissue. ( 27342072 )
2016
50
Inhibitory effects of tetrandrine on epidermal growth factor-induced invasion and migration in HT29 human colorectal adenocarcinoma cells. ( 26648313 )
2016

Variations for Colorectal Adenocarcinoma

Expression for Colorectal Adenocarcinoma

Search GEO for disease gene expression data for Colorectal Adenocarcinoma.

Pathways for Colorectal Adenocarcinoma

Pathways related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.52 BRAF CDK8 CTNNB1 EGFR HRAS KRAS
2
Show member pathways
13 BRAF CDH1 CTNNB1 HRAS KRAS TP53
3
Show member pathways
12.77 BRAF CDH1 CTNNB1 HRAS KRAS TP53
4 12.73 BRAF EGFR HRAS KRAS TP53
5
Show member pathways
12.68 BRAF EGFR HRAS KRAS TP53
6
Show member pathways
12.67 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
7
Show member pathways
12.53 CTNNB1 EGFR HRAS KRAS MSH2 TP53
8 12.51 AURKA CDK8 MLH1 MSH2 TP53
9
Show member pathways
12.5 BRAF EGFR HRAS KRAS TP53
10
Show member pathways
12.46 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
11
Show member pathways
12.41 BRAF CTNNB1 HRAS KRAS
12
Show member pathways
12.41 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
13 12.41 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
14
Show member pathways
12.4 CTNNB1 EGFR HRAS KRAS TP53
15
Show member pathways
12.37 CTNNB1 HRAS KRAS TP53
16
Show member pathways
12.37 BRAF CTNNB1 EGFR HRAS KRAS
17
Show member pathways
12.28 BRAF FGFBP1 HRAS KRAS
18
Show member pathways
12.27 BRAF CDH1 CTNNB1 HRAS
19
Show member pathways
12.25 BRAF EGFR HRAS KRAS TP53
20
Show member pathways
12.25 BRAF EGFR HRAS KRAS TP53
21 12.24 BRAF CTNNB1 EGFR HRAS KRAS TP53
22
Show member pathways
12.23 BRAF HRAS KRAS TP53
23
Show member pathways
12.19 BRAF HRAS KRAS TP53
24
Show member pathways
12.16 BRAF HRAS KRAS TP53
25 12.11 AURKA BRAF EGFR HRAS KRAS
26
Show member pathways
12.1 BRAF EGFR HRAS KRAS
27 12.08 KRAS MLH1 MSH2 TP53
28 12.07 EGFR MLH1 MSH2 TP53
29
Show member pathways
12.06 EGFR HRAS KRAS TP53
30 12.02 CDH1 CTNNB1 HRAS KRAS
31 11.99 BRAF EGFR HRAS KRAS TP53
32 11.98 CTNNB1 HRAS KRAS TP53
33 11.97 CTNNB1 HRAS KRAS TP53
34 11.84 BRAF CTNNB1 EGFR HRAS KRAS TP53
35 11.82 BRAF KRAS TP53
36
Show member pathways
11.81 BRAF HRAS KRAS
37 11.78 BRAF CDH1 CTNNB1 EGFR KRAS MLH1
38 11.75 MLH1 MSH2 TP53
39 11.74 CDH1 CTNNB1 EGFR
40 11.69 HRAS KRAS TP53
41
Show member pathways
11.69 BRAF HRAS KRAS
42 11.65 BRAF HRAS KRAS
43 11.62 EGFR HRAS KRAS TP53
44 11.61 EGFR HRAS KRAS
45 11.6 BRAF CDH1 EGFR HRAS KRAS TP53
46 11.54 EGFR HRAS KRAS
47
Show member pathways
11.44 MLH1 MSH2 TP53
48 11.44 CDH1 CTNNB1 EGFR
49 11.41 AURKA BRAF CDH1 CTNNB1 EGFR KRAS
50 11.33 BRAF HRAS KRAS

GO Terms for Colorectal Adenocarcinoma

Cellular components related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 catenin complex GO:0016342 8.96 CDH1 CTNNB1
2 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.93 CTNNB1 EGFR HRAS PIM2 TP53
2 positive regulation of gene expression GO:0010628 9.92 BRAF CTNNB1 HRAS KRAS TP53
3 positive regulation of transcription, DNA-templated GO:0045893 9.91 CDH1 CDX2 CTNNB1 EGFR PIM2 TP53
4 positive regulation of cell proliferation GO:0008284 9.8 CDX2 CTNNB1 EGFR FGFBP1 HRAS KRAS
5 Ras protein signal transduction GO:0007265 9.76 HRAS KRAS TP53
6 cellular response to drug GO:0035690 9.75 BRAF EGFR TP53
7 positive regulation of MAP kinase activity GO:0043406 9.73 EGFR HRAS KRAS
8 negative regulation of apoptotic process GO:0043066 9.73 AURKA BRAF CEACAM5 EGFR PIM2 TP53
9 epidermal growth factor receptor signaling pathway GO:0007173 9.72 EGFR HRAS KRAS
10 negative regulation of neuron apoptotic process GO:0043524 9.71 BRAF HRAS KRAS MSH2
11 entry of bacterium into host cell GO:0035635 9.6 CDH1 CTNNB1
12 positive regulation of isotype switching to IgG isotypes GO:0048304 9.59 MLH1 MSH2
13 response to isolation stress GO:0035900 9.57 HRAS KRAS
14 ERBB2 signaling pathway GO:0038128 9.54 EGFR HRAS KRAS
15 positive regulation of fibroblast growth factor receptor signaling pathway GO:0045743 9.51 CTNNB1 FGFBP1
16 somatic recombination of immunoglobulin gene segments GO:0016447 9.49 MLH1 MSH2
17 positive regulation of isotype switching to IgA isotypes GO:0048298 9.48 MLH1 MSH2
18 cellular response to indole-3-methanol GO:0071681 9.46 CDH1 CTNNB1
19 negative regulation of cell proliferation GO:0008285 9.43 CTNNB1 FABP6 FGFBP1 HRAS PIM2 TP53
20 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.16 MLH1 MSH2
21 anterior/posterior axis specification GO:0009948 8.8 AURKA CDX2 CTNNB1

Molecular functions related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.86 AURKA BRAF CDK8 EGFR MLH1 MSH2
2 protein kinase binding GO:0019901 9.72 AURKA CTNNB1 EGFR MSH2 TP53
3 protein phosphatase binding GO:0019903 9.54 CTNNB1 EGFR TP53
4 mismatched DNA binding GO:0030983 9.4 MLH1 MSH2
5 double-stranded DNA binding GO:0003690 9.26 CDX2 CTNNB1 EGFR MSH2
6 guanine/thymine mispair binding GO:0032137 9.16 MLH1 MSH2
7 nucleotide binding GO:0000166 9.1 AURKA BRAF EGFR HRAS KRAS PIM2

Sources for Colorectal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....